Author

Juleen Gayed

Institution: Pfizer (United Kingdom)

Observed institutions: University of Iowa, St George's, University of London, Pfizer (United States), Pfizer (United Kingdom), SUNY Upstate Medical University, East West Medical Research Institute

ORCID: 0009-0004-2974-5302

Observed ORCID: 0009-0004-2974-5302

OpenAlex ID: A5010993833

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years

2023 · Patricia Winokur, Juleen Gayed, et al. · New England Journal of Medicine · 111

Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

2024 · Juleen Gayed, Oyeniyi Diya, et al. · Vaccines · 40

Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects

2011 · Atsushi Sugiyama, Yuji Nakamura, et al. · British Journal of Clinical Pharmacology · 18

Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial

2024 · Juleen Gayed, Vishva Bangad, et al. · Vaccines · 12

A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old

2025 · Oyeniyi Diya, Juleen Gayed, et al. · Vaccine · 8

Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial

2025 · Oyeniyi Diya, Juleen Gayed, et al. · Infectious Diseases and Therapy · 3

Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination

2024 · Timothy E. Albertson, Caitlin Hansen, et al. · Infectious Diseases and Therapy · 3

Safety and Immunogenicity of a Fourth Dose of Omicron BA.1–Adapted BNT162b2 COVID-19 Vaccines in Adults 18–55 Years Old

2026 · Patricia Winokur, Oyeniyi Diya, et al. · Clinical Infectious Diseases · 2

A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18–64 Years of Age (Preliminary Results)

2026 · Rucha Dadhe, Juleen Gayed, et al. · Vaccines · 1

Design and rationale of the COVID vaccine-associated myocarditis/pericarditis (CAMP) study

2024 · Dongngan T. Truong, Brian J. Harty, et al. · American Heart Journal · 1

Alternative Methods for the Confirmation of Assay Sensitivity in Thorough Qt Studies

2011 · Jӧrg Täubel, Asif Naseem, et al. · 1

Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive

2026 · David Fitz-Patrick, Omair Sahgal, et al. · Infectious Diseases and Therapy

Safety and Immunogenicity of the BNT162b2 COVID-19 Vaccine in Immunocompromised Participants 2 Years and Older: Results of an Open-Label Phase 2b Study

2026 · Alpana Waghmare, Rucha Dadhe, et al. · Vaccines

A Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination”

2025 · Timothy E. Albertson, Caitlin Hansen, et al. · Infectious Diseases and Therapy

Population joint modeling of SARS-CoV-2 neutralizing titer dynamics after COVID-19 mRNA vaccine booster administration

2025 · Jiawei Zhou, Rohit Rao, et al. · American Conference on Pharmacometrics (ACoP)

Works count: 15

Citation count: 200

H-index: 5

I10-index: 4